GLP-1 and Muscle Loss: How Much of the Lost Weight is Fat and How Much is Muscle?

For many people using GLP-1–based medications, the most visible change is the number on the scale. Weight decreases steadily, often more than expected. However, a quieter question has begun to draw attention: what exactly is being lost?

This is not a trivial concern. Muscle is not only related to body shape but also central to metabolic health. It regulates glucose use, stores energy, and contributes to resting metabolic rate. If a large portion of weight loss comes from muscle, it may influence long-term metabolism and physical strength.

Recent research from 2025 to early 2026 provides a clearer and more balanced picture. The key insight is that muscle loss does occur, but its meaning is more complex than it first appears. Understanding this requires looking beyond total weight and focusing on composition, function, and context.

Weight Loss Always Includes More Than Fat

Any form of weight loss that creates a calorie deficit leads to reductions in both fat mass and lean mass. Lean mass includes muscle, but also organs, body water, and connective tissue. This is a basic physiological rule rather than a feature unique to any specific treatment.

In traditional diet-based weight loss, lean mass typically accounts for about 20% to 30% of total weight lost. This has sometimes been described as the “quarter rule,” meaning roughly one-quarter of weight loss comes from non-fat tissue. The exact proportion depends on age, diet quality, and activity level.

GLP-1 therapies follow the same biological framework. They reduce appetite and calorie intake, creating a sustained energy deficit. As a result, the body draws from both fat and lean reserves. The important question is not whether muscle is lost, but how much, and what that loss represents.

What Recent Data Reveal About Fat and Muscle Distribution

Clinical trials using body composition tools such as DEXA scans offer the most reliable data. These methods can separate fat mass from lean mass and provide a more precise picture than total weight alone.

Data from large trials of semaglutide suggest that about 60% to 75% of weight loss comes from fat mass, while 25% to 40% comes from lean mass [1]. This aligns broadly with earlier expectations but also highlights that lean mass loss is not negligible.

A 2025 systematic review published in Metabolism provided a more detailed comparison. It reported that lean mass accounted for approximately 43% to 45% of weight loss in semaglutide users, while for dual GIP/GLP-1 agonists such as tirzepatide, the proportion was closer to 25.7% [3].

These differences are meaningful. They suggest that not all GLP-1–based therapies affect body composition in the same way. Some may achieve a higher proportion of fat loss relative to muscle, possibly due to differences in hormonal pathways.

Why the Numbers Vary Across Studies

At first glance, these percentages may seem inconsistent. However, much of the variation comes from how lean mass is measured and defined. Lean mass includes multiple tissues, and changes in hydration or glycogen can influence results, especially in the early stages of weight loss.

Another factor is study duration. Short-term studies often show larger fluctuations in lean mass because of rapid changes in fluid balance. Over longer periods, the proportion tends to stabilize, reflecting more sustained tissue changes.

Population differences also matter. Younger individuals with higher baseline muscle mass may lose lean mass differently compared to older adults or those with lower activity levels. These variations are expected and do not necessarily indicate a problem with the treatment itself.

Short-Term vs Long-Term Changes: A Subtle Difference

Recent short-term studies provide useful context. A 2026 study in Diabetes Research and Clinical Practice examined patients using liraglutide over 35 days. It found that while absolute lean mass decreased, the proportion of lean mass relative to total body weight remained stable.

This suggests that early weight loss may not disrupt overall body composition balance. Hormonal markers related to muscle metabolism, such as myostatin and activin, also showed no significant change, indicating that the drug does not directly trigger muscle breakdown pathways in the short term.

Instead, early muscle loss appears to be a passive response to reduced calorie intake. This distinction is important because it separates indirect effects of weight loss from direct pharmacological effects.

Lean Mass Is Not the Same as Muscle

A key point often overlooked is that lean mass is not equivalent to skeletal muscle. It includes organs such as the liver, as well as body fluids and other tissues. During weight loss, reductions in liver size and glycogen stores can contribute significantly to lean mass changes.

A 2026 study in Cell Reports Medicine showed that GLP-1 therapies reduce fat mass more rapidly than muscle mass. In both animal and human data, liver mass decreased notably, while skeletal muscle changes were smaller and more gradual [4].

This means that part of what is labeled as “muscle loss” may actually reflect changes in other tissues. Without direct measurement of muscle function, it is easy to overestimate the impact on skeletal muscle.

Muscle Quality: An Overlooked Dimension

Focusing only on the quantity of muscle can be misleading. Muscle quality, which includes fiber composition and metabolic efficiency, may be equally important.

In individuals with obesity, muscle often contains fat deposits within the tissue, a condition sometimes described as myosteatosis. This reduces insulin sensitivity and impairs metabolic function. Losing this type of “low-quality” muscle may not be harmful and could even be beneficial.

A 2026 review in Comprehensive Physiology suggested that GLP-1 therapies may improve muscle microcirculation and enhance the delivery of nutrients and insulin to muscle tissue. This can increase the functional efficiency of the remaining muscle.

Some imaging studies also suggest that fat-rich muscle fibers are more likely to be reduced during weight loss, while healthier fibers are relatively preserved. This points toward a process of “quality optimization” rather than simple loss.

Does Muscle Function Decline?

From a clinical perspective, function matters more than mass. Muscle strength, endurance, and mobility are more directly linked to daily life and long-term health.

A review published in Acta Diabetologica in 2025 found that although lean mass decreased in patients using GLP-1 therapies, there was no clear evidence of reduced physical function. In some cases, mobility and endurance remained stable or improved [5].

Experimental data support this observation. In animal models, GLP-1 treatment reduced body weight while maintaining or even improving running performance. In human studies, relative muscle strength often improved when adjusted for body weight.

These findings suggest that losing some muscle mass does not automatically translate into weaker function. In fact, reduced body weight can make movement more efficient, offsetting part of the loss.

Who May Be More Vulnerable?

Not all individuals respond in the same way. Older adults, particularly those with low baseline muscle mass, may be at higher risk of sarcopenia during weight loss.

A study of older patients with type 2 diabetes reported that after 24 months of semaglutide use, about 27.7% met criteria for sarcopenia. Measures such as grip strength and walking speed declined in this group.

However, researchers noted that this population already had a higher baseline risk. The findings likely reflect a combination of aging, disease, and weight loss rather than a direct harmful effect of the medication alone.

This highlights the importance of individualized assessment. The same treatment can have different implications depending on starting conditions.

Comparing GLP-1 With Other Weight Loss Methods

A common question is whether GLP-1 therapies cause more muscle loss than traditional approaches. Current evidence suggests that the proportion of lean mass loss is broadly similar to diet-induced weight loss.

The difference lies in scale. GLP-1 therapies often produce larger total weight reductions. As a result, the absolute amount of both fat and lean mass lost is higher, even if the proportion remains comparable.

This distinction is important. It explains why muscle loss may appear more pronounced without indicating a fundamentally different biological process.

Practical Strategies to Support Muscle Health

While muscle loss cannot be completely avoided, it can be influenced. Evidence consistently highlights the role of nutrition and physical activity in shaping body composition during weight loss.

Protein intake is particularly important. During weight loss, requirements are often higher than during maintenance. A commonly suggested range is 1.2 to 1.5 grams per kilogram of body weight per day, distributed evenly across meals.

Physical activity also plays a central role. General guidelines recommend at least 150 minutes of moderate exercise per week, but higher levels may be needed to support weight loss. Resistance training, performed two to three times per week, provides a direct stimulus for maintaining muscle.

Balanced nutrition remains essential. Reduced calorie intake can lead to lower intake of vitamins and minerals. Monitoring nutrients such as vitamin D, iron, and B12 may be useful, especially in long-term use.

Hydration is another practical factor. Reduced food intake may unintentionally reduce fluid intake, which can affect overall metabolism and well-being.

A Shift Toward “Quality-Oriented” Weight Loss

The discussion around GLP-1 therapies is gradually evolving. Instead of focusing only on how much weight is lost, attention is shifting toward the composition and quality of that loss.

Emerging treatments reflect this shift. The BELIEVE trial, published in Nature Medicine in 2026, studied a combination of semaglutide and bimagrumab, a drug targeting muscle growth pathways. The results showed that 92% of weight loss came from fat, with only 2.9% from lean mass.

This contrasts with semaglutide alone, where about 7.4% of weight loss came from lean mass. The combination also led to greater reductions in visceral fat, suggesting a more targeted effect.

Although still experimental, these findings point toward a future where weight loss therapies can be designed to preserve muscle more effectively.

Conclusion

Muscle loss during GLP-1–induced weight loss is real, but it is often misunderstood. Current evidence suggests that about 25% to 45% of weight loss may come from lean mass, depending on the drug and population.

This pattern is not unique to GLP-1 therapies. It reflects the body’s natural response to a sustained calorie deficit. Importantly, lean mass loss does not equal muscle loss alone and does not necessarily lead to reduced function.

In many cases, muscle quality improves, and physical performance remains stable. The key is to view weight loss in context, considering both composition and overall health outcomes.

Looking ahead, a more refined approach is emerging. Future therapies and strategies aim to shift weight loss toward fat while preserving muscle. Until then, balanced nutrition and regular resistance training remain effective ways to support muscle health.

References：

[1] Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

[2] Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

[3] Zhang, Y., et al. (2025). Body composition changes with GLP-1 receptor agonists: A systematic review and network meta-analysis. Metabolism. https://www.sciencedirect.com

[4] Langer, H. T., et al. (2026). Weight loss with GLP-1 medicines does not result in disproportionate muscle loss. Cell Reports Medicine, 7(3). https://www.cell.com

[5] Bianchi, L., et al. (2025). Lean mass and physical function during GLP-1 therapy. Acta Diabetologica. https://link.springer.com

Author Information

Dr. Michael Zhang is a medical writer and researcher specializing in endocrinology and metabolic health. He has over ten years of experience analyzing clinical trials and translating complex medical evidence into clear, reliable information for general audiences. His work focuses on obesity, diabetes, and emerging therapies, with an emphasis on evidence-based interpretation and practical relevance. He follows internationally recognized principles such as European Association of Endocrinology and Therapeutics to ensure accuracy, transparency, and trustworthiness in health communication, helping readers make informed decisions based on current scientific understanding.

Disclaimer

This article is for educational purposes only and reflects current evidence as of 2026. It does not replace medical advice, diagnosis, or treatment. Individual health decisions should be made in consultation with a qualified healthcare provider, based on personal medical history and risk factors.